Ocuphire Corporation (OCUP) - Long-Term Debt to Capital Coefficient
The price action for Ocuphire Pharma, Inc. (OCUP) shown on this chart highlights expectations for the Nyxol eye drop trials against presbyopia, where FDA approval and the alliance with Viatris will serve as key drivers. Meanwhile, the indicator stands at 0.00. Manufacturing processes are delegated to external CMOs and governed by strict contracts. Portfolio diversification through the development of retinal therapies minimizes risks.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_OCUP_-_Ocuphire-Pharma-Inc._-_Long-Term-Debt-to-Capital "OCUP: Ocuphire Pharma Long-Term Debt to Capital 07/04/2022 - 10/24/2024 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Ocuphire Pharma, Inc. (OCUP)
This ratio compares the volume of credit obligations with a maturity of over one year to the amount of equity. The metric determines the extent to which the issuer's financial stability depends on borrowed funds over the long term. For Ocuphire Pharma, Inc. (OCUP), this is critical when financing APX3330 clinical trials and launching Ryzumos to market. By analyzing the dynamics of the long-term debt-to-equity ratio, an investor assesses debt service risks. High leverage may limit the investment potential of the ophthalmology portfolio.